Pharmaceutical Right to Try laws give terminally ill patients access to therapies that have passed Phase I testing but have not achieved US Food and Drug Administration approval. The FDA’s current program, expanded access, already gives these patients access to experimental drugs, but Right to Try laws expedite the process and reduce the FDA’s role in it, comments Dr Nicola Davies in her monthly FDA blog for The Pharma Letter. 12 March 2018